APA (7th ed.) Citation

TA, E., Y, S., O, H., Y, S., W, J., JS, F., . . . M, W. (2026). Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2600550. https://doi.org/10.1200/JCO-26-00550

Chicago Style (17th ed.) Citation

TA, Eyre, et al. "Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 2026: JCO2600550. https://doi.org/10.1200/JCO-26-00550.

MLA (9th ed.) Citation

TA, Eyre, et al. "Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2026, p. JCO2600550, https://doi.org/10.1200/JCO-26-00550.